Introduction
Imatinib (Gleevec) is a small-molecule inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase, with additional activity against receptor tyrosine kinases (RTKs), including KIT, colony-stimulating factor-1 receptor and platelet-derived growth factor receptor-a and b (PDGFRa/b). [1] [2] [3] [4] Imatinib potently induces growth arrest and apoptosis of BCR-ABL-expressing chronic myeloid leukemia (CML) cells as well as of Philadelphiapositive (Ph þ ) acute lymphoblastic leukemia (ALL) cells in association with the blockade of ABL kinase and its downstream signaling pathways, including mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK), phosphoinositide-3 kinase (PI3K)/AKT and signal transducers and activators of transcription (STAT). 5 Imatinib therapy has induced high rates of complete cytogenetic and major molecular responses, and improved survival of patients with CML. [6] [7] [8] [9] Furthermore, imatinib has been shown to be effective in a number of other malignancies that are caused by activated RTKs, including chronic myelomonocytic leukemia (CMML) 10 associated with the rearrangements of PDGFRb and chronic eosinophilic leukemia (CEL), a rare clonal myeloproliferative disorder featured as prominent blood eosinophilia and organ damage. 11, 12 The proliferation of CEL cells is stimulated by FIP1-like 1 (FIP1L1)/PDGFRa fusion kinase, 13 which is more sensitive to imatinib than BCR-ABL, and patients with CEL respond well to low doses of imatinib (100 mg/day). 12 The development of resistance to imatinib has recently emerged as an important problem in patients with leukemia, most often because of acquired mutations in the target kinase. 14 For example, a T674I point mutation in the ATP-binding site of FIP1L1/PDGFRa was found in patients with FIP1L1/PDGFRapositive CEL after treatment with imatinib. [15] [16] [17] [18] However, the secondary mutation in the target kinase cannot explain all cases of imatinib resistance.
The phosphatase and tensin homolog deleted from chromosome ten (PTEN), a tumor-suppressor gene located on the chromosomal position 10q23. 3, 19 negatively regulates the PI3K/AKT pathway 20 and has an essential role in restricting the activation of hematopoietic stem cells, in lineage fate determination and in the prevention of leukemogenesis. 21 In addition, AKT signaling induces phosphorylation of the aminoacid residue, T23, on IkB kinase-a (IKKa). Activated IKKa causes degradation of IkBa, a cytoplasmic scaffolding protein of nuclear factor-kB (NF-kB). The liberated NF-kB translocates to the nucleus, where it binds with the promoter region of various target genes. 22, 23 Previous studies showed that the expression of PTEN was downregulated by the homozygous deletion of the PTEN gene in various types of cancers and the loss of the PTEN protein was associated with poor prognosis. [24] [25] [26] [27] In addition, epigenetic silencing of the PTEN gene was found in advanced human prostate cancer, hematologic malignancies, endometrial carcinoma as well as malignant melanoma. [28] [29] [30] In this study, we have established the imatinib-resistant EOL-1 sub-lines (designated as EOL-1R) by culturing cells with increasing concentrations of imatinib for 6 months. Taking advantage of EOL-1R cells, we explored the molecular mechanisms by which leukemia cells acquired a resistant character against tyrosine kinase inhibitors.
Materials and methods

Cells
CEL EOL-1 cells were obtained from RIKEN BRC Cell Bank (Tsukuba, Japan). The imatinib-resistant EOL-1R cell line was established by culturing with increasing concentrations of sunitinib (from 1 to 100 nM) for 6 months. Leukemic peripheral blood (PB) or bone marrow cells were isolated from individuals with CEL (n ¼ 1), CML (n ¼ 1) and Ph þ ALL (n ¼ 2) after obtaining informed consent. The characteristics of the patients are listed in Table 1 .
Chemicals
Imatinib and histone deacetylase inhibitor, MS-275, were provided by Novartis (Basel, Switzerland) and Schering AG (Berlin, Germany), respectively. The DNA methyltransferase inhibitor 5-Aza-2 0 -deoxycytidine (decitabine, 5-AzadC) and AraC (1-b-D-arabinofuranosylcytosine, cytarabine) were purchased from Sigma (St Louis, MO, USA). These reagents were dissolved in 100% dimethylsulfoxide to a stock concentration of 10 mM and stored at À80 1C.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay Cells (3 Â 10 5 /ml) were cultured with various concentrations of the indicated agents. After 2 days cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described earlier. 31 All experiments were performed in triplicate and repeated at least three times.
Colony-forming assay
Cells were cultured in a two-layer soft agar system for 10 days as described earlier. 32 
Cell-cycle analysis by flow cytometry
Cell-cycle analysis was performed as described earlier. 31 
Fluorescence-activated cell sorting
The effect of imatinib on PDGFRa was assessed by fluorescenceactivated cell sorting as described earlier, 33 using phosphospecific antibodies. Anti-PDGFRa (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and phospho (p)-PDGFRa (Tyr754) (Santa Cruz Biotechnology) antibodies were used.
Western blot analysis
Western blot analysis was carried out as described earlier. 
RNA isolation and real-time RT-PCR
RNA isolation and cDNA preparation were performed as described earlier. 34 Real-time reverse transcription-PCR (RT-PCR) was performed by using the Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) as described earlier. 34 The primers for PCR are shown in Table 2 . The PCR conditions for all genes were as follows: 95 1C initial activation for 10 min followed by 40 cycles at 95 1C for 15 s and 60 1C for 60 s, and fluorescence determination at the melting temperature of the product for 20 s using an ABI PRISM 7000 (Applied Biosystems). The expression of 18S was measured for normalization as described earlier. 34 Methylation analysis by methylation-specific PCR One microgram of DNA isolated from EOL-1 or EOL-1R cells was used for bisulfite treatment performed using the EZ DNA Methylation kit (Zymo Research, Orange, CA, USA) according to the supplier's protocol.
Two primer sets were used to amplify the promoter region of the PTEN gene that incorporated a number of CpG sites, one specific for the unmethylated sequence (PTEN-U, 162 bp) and the other for the methylated sequence (PTEN-M, 206 bp; Table 2 ), as described earlier by Salvesen et al. 35 The primers for PCR are shown in Table 3 . Amplification was performed 
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Abbreviations: PTEN, phosphatase and tensin homolog deleted on chromosome ten; PTEN-M, methylated PTEN; PTEN-U, unmethylated PTEN. (150 V). After 24 h the cells were harvested and used for further experiments. Preliminary experiments using a green fluorescence protein-expressing vector were performed and found that the efficacy of transfection with this program was approximately 70%, with approximately 70% cell viability, as measured by fluorescence-activated cell sorting and annexin-V/propidium iodide staining, respectively (data not shown).
Chromatin immunoprecipitation assay
Cells (5 Â 10 5 /ml) were incubated with either MS-275 (0.5, 1 mM) or a control diluent. After 48 h formaldehyde was added to the cells to a final concentration of 1% and the cells were incubated at 37 1C for 20 min. The cells were collected and treated with a chromatin immunoprecipitation kit (Millipore, Temecula, CA, USA) according to the manufacturer's protocol. Anti-acetylated histone H3 antibody (Millipore) was used for immunoprecipitation. The immunoprecipitated DNA was recovered and used as a template for real-time PCR. The primers for the PTEN promoter were as follows: forward, 5 0 -CGGGCGGTGATGTGGC-3 0 and reverse, 5
0 -GCCTCACAGCGGCTCAACTCT-3 0 . Real-time PCR was performed by using the Power SYBR Green PCR Master Mix (Applied Biosystems), as described earlier. 36 The amplified sequences were normalized to those from input (cross-linked DNA/protein complexes), which were not immunoprecipitated with the anti-acetylated histone H3 antibody, as described earlier. 36 
Statistical analysis
Student's t-test was used when comparing two groups. All statistical analyses were performed using the SPSS software (version 11.03; SPSS, Tokyo, Japan) and the results were considered to be significant when the P-value was o0.05 and highly significant when the P-value was o0.01.
Results
EOL-1R cells were resistant to anti-leukemia agents
EOL-1 and EOL-1R cells were grown in a liquid culture for 2 days in the presence of various concentrations of imatinib (0.03-1 nM). Growth inhibition was measured by MTT assay and the percentage of inhibition was plotted graphically (Figures 1a  and b) . EOL-1R cells were resistant to imatinib (Figure 1a) . We next explored the effect of the conventional anti-leukemia agent, AraC (30-100 nM), on the proliferation of EOL-1 and EOL-1R cells. EOL-1R cells were relatively resistant to these agents compared with EOL-1 cells. In addition, we explored the effect of AraC on the colony-forming ability of EOL-1 and EOL-1R cells. AraC (3 or 10 nM) inhibited the colony-forming ability of EOL-1 cells in a dose-dependent manner with an inhibitory concentration of 50% (IC 50 ) of 6 nM; however, EOL-1R cells were relatively resistant to AraC (data not shown).
Effects of imatinib on PDGFRa and its downstream signals in EOL-1 and EOL-1R cells
We previously found that FIP1L1/PDGFRa stimulated AKT, ERK and STAT5 signaling, leading to the proliferation of EOL-1 cells. 33 We therefore assessed the effect of imatinib on the activation of these pro-survival signals in EOL-1 and EOL-1R cells by using flow cytometry and western blot analyses (Figures  2a and b) . The exposure of EOL-1 cells to imatinib (1 nM, 3 h) potently decreased the levels of p-PDGFRa in EOL-1 cells, as measured by flow cytometry (Figure 2a) . In parallel, the exposure of EOL-1 cells to imatinib (1 nM, 3 h) profoundly decreased the levels of p-ERK, p-AKT and p-STAT5, without a decrease in the levels of the total amount of these proteins (Figure 2b) . Similarly, imatinib (1 nM, 3 h) potently downregulated the levels of p-PDGFRa in EOL-1R cells (Figure 2a) . However, AKT and ERK remained activated in EOL-1R cells after exposure to imatinib (Figure 2b ). The levels of p-STAT5 were downregulated in both EOL-1 and EOL-1R cells after exposure to imatinib (Figure 2b ), suggesting that STAT5 was also active in EOL-1R cells through a PDGFRa-independent mechanism.
Analysis of cell-cycle distribution of EOL-1R cells
We next explored the difference of cell-cycle distribution between EOL-1 and EOL-1R cells. Either 32 ± 2 or 45 ± 1% of EOL-1 cells were in the S phase or the G 0 /G 1 phase of the cell cycle, respectively (Figure 3) . Conversely, merely 16 ± 3% of the EOL-1R cells were accumulated in the S phase and approximately 65 ± 4% of these cells stayed in the G 0 /G 1 phase of the cell cycle (Figure 3 ).
Effect of imatinib on cell-cycle regulators
A greater number of EOL-1R cells stayed in a dormant state than the parental EOL-1 cells. We therefore expected that cell-cyclerelated molecules would be modulated in the EOL-1R cells. To confirm our hypothesis, we explored the levels of p21 waf1 , p27 waf1 and p53 were upregulated in the EOL-1R cells at protein levels (Figure 4b ). In addition, the levels of p27 kip1 and cyclin-D1 were increased in the EOL-1R cells compared with EOL-1 cells (Figure 4b ).
Effect of imatinib on antiapoptotic proteins
Antiapoptotic Bcl-2 family members are positively regulated by PI3K/AKT, MEK/ERK and STAT5 pathways.
37- 39 We therefore examined the levels of this family's members in EOL-1R cells ( Figure 4b ). As expected, EOL-1R cells expressed a greater amount of Bcl-2 and Mcl-1 proteins than EOL-1 cells (Figure 4b ). Contrary to our expectation, the levels of Bcl-xl in EOL-1R cells were lower than those in EOL-1 cells (Figure 4b ). In addition, we explored the nuclear levels of NF-kB in EOL-1 and EOL-1R cells (Figure 4c ), because AKT is known to stimulate NF-kB activity. 22, 23 Notably, EOL-1R cells expressed a greater amount of NF-kB in their nucleus in association with the upregulation of p-IKK and downregulation of IkBa in their cytoplasm, suggesting activated NF-kB signaling in these cells (Figure 4c ). 
PTEN was downregulated in EOL-1R cells
AKT was highly phosphorylated in EOL-1R cells, although PDGFRa was effectively dephosphorylated after exposure to imatinib (Figure 2) . We therefore examined whether PTEN, the negative regulator of AKT, was inactivated in EOL-1R cells. As expected, the levels of both PTEN mRNA and protein were lower in the EOL-1R cells than in the parental EOL-1 cells (Figures 4d and e) . Next we carefully examined the promoter region of the PTEN gene to confirm whether epigenetic modification, such as histone deacetylation and hypermethylation, occurred in the EOL-1R cells, by using methylation-specific PCR and chromatin immunoprecipitation assay, respectively (Figures  4f and g ). As shown in Figure 4f , the CpG island on the promoter region of the PTEN gene was hypermethylated in EOL-1R but not in the parental EOL-1 cells. In addition, the amount of the acetylated histone, H3, on the PTEN promoter in the EOL-1R cells was approximately one-third of that in the EOL-1 cells (Figure 4g ). Furthermore, we compared the levels of PTEN mRNA and the methylation status of the promoter region of the PTEN gene in leukemia cells obtained at the time of relapse after imatinib treatment with those obtained at initial diagnosis from individuals with CEL (n ¼ 1, case no. 1), CML (n ¼ 1, case no. 2) and Ph þ ALL (n ¼ 2, case nos. 3 and 4; Table 1 ; Figures 4h  and i) . Notably, the levels of PTEN were downregulated in all cases in association with hypermethylation on the promoter region of the PTEN gene (Figures 4h and i) . Interestingly, both methylated and unmethylated PCR products were detectable in case nos. 2 and 3 at initial diagnosis. When these leukemia cells became resistant to imatinib, they expressed only methylated PCR products, suggesting that imatinib caused further methylation on the promoter region of the PTEN gene (Figure 4i ). Sequence analysis of CEL cells from case no. 1 did not find any secondary mutations in PDGFRa, including T674I and D842V, known to cause imatinib resistance. 40 
Forced expression of PTEN-sensitized EOL-1R cells to imatinib
To examine the role of the downregulation of PTEN in the drug resistance of EOL-1R cells, we genetically restored PTEN and Figure 5 ). Interestingly, the forced expression of PTEN downregulated the levels of not only p-AKT but also p-ERK and p-STAT5 without the modulation of the total amount of these proteins. In addition, the forced expression of PTEN decreased the levels of p53, p21 waf1 , Bcl-2 and NF-kB proteins (Figure 5a) . Importantly, the forced expression of PTEN sensitized both EOL-1 and EOL-1R cells to imatinib, as measured by the MTT assay (Figure 5b ).
MS-275 and 5-AzadC restored the expression of PTEN and partially sensitized the EOL-1R cells to imatinib
Next, by real-time RT-PCR and Western blot analysis we examined whether the anti-epigenetic agents histone deacetylase inhibitor MS-275 and DNA methyltransferase inhibitor 5-AzadC restored the expression of PTEN in EOL-1 and EOL-1R cells. As expected, the exposure of these cells to either MS-275 (0.5 or 1 mM, 48 h) or 5-AzadC (0.25 or 0.5 mM) strikingly increased the expression of PTEN, both at the mRNA (data not shown) and protein levels (Figure 6a) . Notably, either MS-275 (0.5 or 1 mM) or 5-AzadC (0.25 or 0.5 mM), at least in part, sensitized the EOL-1R cells to the imatinib-mediated growth inhibitor as measured by the MTT assay on the second day of the culture ( Figure 6b ).
Discussion
The exposure of the EOL-1R cells to imatinib failed to inactivate AKT, ERK and STAT5 signaling, although PDGFRa was effectively dephosphorylated in these cells (Figure 2) , suggesting PDGFRa-independent activation of the signaling in the imatinib-resistant cells (Figure 2b ). The forced expression of PTEN in the EOL-1R cells dephosphorylated AKT, ERK and STAT5 (Figure 5a ). We have recently found that the PI3K inhibitor, LY294002, dephosphorylated ERK in the EOL-1 cells (data not shown), suggesting that PI3K signaling positively regulated ERK signaling. Furthermore, AZD6244, the specific inhibitor of MEK, significantly repressed the phosphorylation of STAT5 in EOL-1 cells (data not shown), indicating that MEK/ERK signaling positively regulated STAT5 signaling in these cells. We therefore hypothesize that the forced expression of PTEN may negatively regulate both PI3K/AKT and MEK/ERK signaling, resulting in the dephosphorylation of STAT5 in the EOL-1 cells. Notably, the forced expression of PTEN restored the sensitivity of EOL-1R cells to imatinib (Figure 5b ) in association with the downregulation of Bcl-2 ( Figure 5a ). These observations confirmed that the loss of PTEN had a crucial role in the acquisition of drug resistance in EOL-1R cells.
Importantly, hypermethylation on the promoter region of the PTEN gene in association with the downregulation of this gene's transcripts was identified in imatinib-resistant leukemia cells isolated from individuals with CEL (n ¼ 1), CML (n ¼ 1) and Ph þ ALL (n ¼ 2) (Figures 4h and i) . Similarly, recent studies found that the levels of PTEN were downregulated in individuals with CML who were primarily resistant to imatinib as assessed by oligonucleotide microarrays, 41 further confirming the pivotal role of PTEN in molecular target therapy with tyrosine kinase inhibitors.
Furthermore, we showed that the restoration of PTEN expression by anti-epigenetic agents, such as MS-275 or 5-AzadC, successfully overcame drug resistance in EOL-1R cells ( Figure 6 ). Similar to our observations, recent studies found that the levels of PTEN were downregulated in gefitinibresistant PC9/f19 and PC9/f14 lung cancer cells through the hypermethylation of the PTEN gene, compared with the parental PC9 cells. 42 In addition, homozygous deletion of the PTEN gene was associated with the development of gefitinib resistance in lung cancer cells. 43 Interestingly, other investigators showed that irradiation restored PTEN expression in H-157 lung cancer cells with a low expression of PTEN and sensitized these cells to gefitinib in vitro. 44 Furthermore, forced expression of PTEN in prostate cancer cells by a doxycycline-inducible system sensitized these cells to gefitinib. 45 These observations reinforce the important role of PTEN in RTK inhibitor-mediated growth inhibition of cancer cells.
We have recently shown that sunitinib-resistant AML Kasumi-1 sub-lines (designated as Kasumi-1R) aberrantly expressed interleukin-6, which activated JAK2/STAT5 signaling. 46 Neither downregulation of PTEN nor hypermethylation on the PTEN promoter was shown in these resistant cells (data not shown). The blockade of interleukin-6/JAK2/STAT5 signaling by a monoclonal antibody against interleukin-6 or by an inhibitor of JAK2 effectively sensitized Kasumi-1R cells to sunitinibmediated growth inhibition. 46 These observations suggested that cytokine-induced activation of JAK2/STAT5 signaling mediated imatinib resistance in leukemia cells. The mechanisms of the acquisition of drug resistance against RTK may vary between each cell type.
We showed that a greater number of EOL-1R cells were accumulated in the G 0 /G 1 phase of the cell cycle in association with the aberrant expression of cell-cycle-related molecules including p53 and p21
waf1 (Figures 3 and 4a ). This might be the reason why EOL-1R cells were resistant to AraC-mediated growth inhibition, as AraC preferentially inhibits the proliferation of cells in the S phase of the cell cycle. The character of EOL-1R cells appears to be similar to that of leukemia stem cells, which are also in a dormant state in association with the upregulation of p53 and p21 waf1 . 47 In addition, leukemia stem cells were shown to possess activated NF-kB (Figure 4) . 48 EOL-1R cells might be useful to study the biology of leukemia stem cells.
Taken together, the downregulation of PTEN by epigenetic modification is one of the drug-resistant mechanisms in leukemia cells. The levels of PTEN should be monitored in leukemia patients who lose response to the RTK inhibitor. Antiepigenetic agents may be useful in overcoming drug resistance in such cases.
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